Qingdao NovelBeam Technology (688677) Fundamentals 2026 — P/E 52.0x, Revenue Analysis | SniperIQ
Qingdao NovelBeam Technology (688677) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥9.0B, trading at ¥75.35 on the SHH. This SniperIQ fundamentals page covers Qingdao NovelBeam Technology's valuation (P/E 52.0x, P/B 6.4x), profitability (net margin 27.3%), revenue (¥603M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Qingdao NovelBeam Technology's market cap?
Qingdao NovelBeam Technology (688677) has a market capitalization of approximately ¥9.0B, trading at ¥75.35 on the SHH. Market cap moves with the live share price.
What is Qingdao NovelBeam Technology's P/E ratio?
Qingdao NovelBeam Technology's trailing twelve-month P/E ratio is 52.0x, with a price-to-book (P/B) of 6.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Qingdao NovelBeam Technology?
Qingdao NovelBeam Technology runs a net profit margin of 27.3%, a gross margin of 98.1%, and an operating margin of 30.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Qingdao NovelBeam Technology generate?
Qingdao NovelBeam Technology reported revenue of ¥603M for fiscal year 2025, with net income of ¥171M and earnings per share (EPS) of 1.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Qingdao NovelBeam Technology pay a dividend?
Qingdao NovelBeam Technology offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Qingdao NovelBeam Technology financially healthy?
Qingdao NovelBeam Technology carries a debt-to-equity ratio of 0.07x and a current ratio of 5.17x, with a market beta of 0.65. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Qingdao NovelBeam Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qingdao NovelBeam Technology (688677) the key facts are: market cap ¥9.0B, P/E 52.0x, revenue ¥603M, 52-week range 36.01-171. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Qingdao NovelBeam Technology's full fundamentals live
Get Qingdao NovelBeam Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.